Clinical Trial: A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO(R) for 12 Months

U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06385509) titled 'A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO(R) for 12 Months' on April 19.

Brief Summary: TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.

Study Type: Interventional

Condition: Hypogonadism

Intervention: Drug: Jatenzo

237 mg JATENZO twice daily

Recruitment Status: Not Yet Recruiting

Published by HT Digital Content Services with permission from Health Daily Digest....